Bank Of America Corp Gracell Biotechnologies Inc. Transaction History

Bank Of America Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.43 - $10.04 $1.24 Million - $5.12 Million	509,655 Added 22178.2%	511,953 $5.14 Million
Q2 2023 Aug 14, 2023	SELL	$1.45 - $6.07 $8,447 - $35,363	-5,826 Reduced 71.71%	2,298 $8,000
Q1 2023 May 12, 2023	BUY	$1.8 - $2.5 $6,913 - $9,602	3,841 Added 89.68%	8,124 $15,000
Q4 2022 Feb 10, 2023	SELL	$2.08 - $3.96 $53,992 - $102,793	-25,958 Reduced 85.84%	4,283 $9,000
Q3 2022 Nov 14, 2022	SELL	$2.08 - $5.15 $58,695 - $145,327	-28,219 Reduced 48.27%	30,241 $97,000
Q2 2022 Aug 12, 2022	SELL	$1.95 - $5.5 $54,100 - $152,592	-27,744 Reduced 32.18%	58,460 $321,000
Q1 2022 May 16, 2022	SELL	$1.83 - $5.52 $252 - $761	-138 Reduced 0.16%	86,204 $200,000
Q4 2021 Feb 08, 2022	BUY	$5.65 - $14.9 $351,712 - $927,525	62,250 Added 258.38%	86,342 $522,000
Q3 2021 Nov 15, 2021	BUY	$9.91 - $14.84 $238,751 - $357,525	24,092 New	24,092 $334,000

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.